Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.

scientific article published on 4 February 2005

Conventional cytogenetics of myeloproliferative diseases other than CML contribute valid information. is …
instance of (P31):
scholarly articleQ13442814

External links are
P356DOI10.1007/S00277-004-0977-1
P698PubMed publication ID15692838

P50authorTorsten HaferlachQ66370751
Claudia SchochQ66370757
Ulrike BacherQ66370775
Susanne SchnittgerQ66370791
P2093author name stringWolfgang Kern
Wolfgang Hiddemann
P433issue4
P921main subjectcytogeneticsQ246128
P304page(s)250-257
P577publication date2005-02-04
P1433published inAnnals of HematologyQ15766509
P1476titleConventional cytogenetics of myeloproliferative diseases other than CML contribute valid information.
P478volume84

Reverse relations

cites work (P2860)
Q64988628A Novel Acquired t(2;4)(q36.1;q24) with a Concurrent Submicroscopic del(4)(q23q24) in An Adult with Polycythemia Vera.
Q38089228Advances in molecular diagnostics of myeloproliferative disorders
Q38012085Chronic myelomonocytic leukemia: 2012 update on diagnosis, risk stratification, and management
Q38130476Chronic myelomonocytic leukemia: 2013 update on diagnosis, risk stratification, and management
Q79241949Chronic myelomonocytic leukemia: The role of bone marrow biopsy immunohistology
Q34405385Cytogenetic abnormalities in essential thrombocythemia at presentation and transformation
Q35162458Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institution
Q47908421Detection of mutations in JAK2 exons 12-15 by Sanger sequencing
Q35849674Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model
Q54351232Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Q26770330Genomic diversity in myeloproliferative neoplasms: focus on myelofibrosis
Q38134374Management recommendations for chronic myelomonocytic leukemia: consensus statements from the SIE, SIES, GITMO groups
Q37202615Minimal residual disease diagnostics in myeloid malignancies in the post transplant period
Q37255020Pathogenetic insight and prognostic information from standard and molecular cytogenetic studies in the BCR-ABL-negative myeloproliferative neoplasms (MPNs).
Q41609451Prognostic impact of acquisition of cytogenetic abnormalities during the course of chronic myelomonocytic leukemia
Q51822948Quantitative assay for Janus kinase 2 (JAK2) mutation in Chinese patients with chronic myeloproliferative disorders.
Q28307278Recent advances in diagnosis, molecular pathology and therapy of chronic myelomonocytic leukaemia
Q37274983Significance of cytogenetic abnormalities in patients with polycythemia vera
Q43057954Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia
Q40170336Successful management of acute myeloid leukemia transformed from chronic myelomonocytic leukemia in the elderly by a combination regimen of decitabine and cytarabine, aclarubicin and granulocyte colony-stimulating factor: A case report
Q24675681The diagnosis of BCR/ABL-negative chronic myeloproliferative diseases (CMPD): a comprehensive approach based on morphology, cytogenetics, and molecular markers
Q36967029Treatment with Hypomethylating Agents before Allogeneic Stem Cell Transplant Improves Progression-Free Survival for Patients with Chronic Myelomonocytic Leukemia

Search more.